Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the Effectiveness and Impact of Nirsevimab Administered as Routine Immunization

Next Previous
Search
Trial Profile

Evaluation of the Effectiveness and Impact of Nirsevimab Administered as Routine Immunization

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nirsevimab (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Therapeutic Use
  • Acronyms NIRSE-GAL

    • Most Recent Events

    • 02 May 2024 According to a Sanofi media release, study conducted in Galicia, Spain under a collaborative framework with the Galician Directorate of Public Health of the Xunta de Galicia (Galician government) and Sanofi.
    • 02 May 2024 According to a Sanofi media release, Beyfortus reduced respiratory syncytial virus (RSV) hospitalizations by 82% in infants under 6 months of age, compared to infants who received no RSV intervention, according to the interim results of an ongoing study published in The Lancet.
    • 02 May 2024 According to a Sanofi media release, Federico Martinon Torres, Head of Pediatrics, Hospital Clinico Universitario Santiago, Spain is the principal investigator of NIRSE-GAL study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top